CDA | Evidence Driven
CDA | Evidence Driven

Avastin for Ovarian Cancer - Details

Details

Files
Generic Name:
Bevacizumab
Project Status:
Complete
Therapeutic Area:
Ovarian Cancer
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Avastin
Project Line:
Reimbursement Review
Project Number:
PC0047-000
Performance Metric:
N/A — Predated performance metrics
Strength:
25mg/mL
Tumour Type:
Gynecology
Indications:
Ovarian Cancer
Funding Request:
In combination with paclitaxel and carboplatin for the front-line treatment of epithelial ovarian, fallopian tube or primary peritoneal cancer patients with high risk of relapse (stage III sub-optimally debulked, or stage III unresectable, or stage IV patients
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Bevacizumab (Avastin) Ovarian Cancer – Final Recommendation Final Recommendation June 4, 2015 View PDF
Bevacizumab (Avastin) Ovarian Cancer - Final Clinical Guidance Report Guidance Reports June 4, 2015 View PDF
Bevacizumab (Avastin) Ovarian Cancer - Final Economic Guidance Report Guidance Reports June 4, 2015 View PDF
Bevacizumab (Avastin) Ovarian Cancer - Initial pERC Recommendation Initial Recommendation April 2, 2015 View PDF
Bevacizumab (Avastin) Ovarian Cancer – PAG Feedback on Initial Recommendation Feedback June 4, 2015 View PDF
Bevacizumab (Avastin) Ovarian Cancer – Manufacturer Feedback on Initial Recommendation Feedback June 4, 2015 View PDF
Bevacizumab (Avastin) Ovarian Cancer – Patient Advocacy Group (OCC) Feedback on Initial Recommendation Feedback June 4, 2015 View PDF
Bevacizumab (Avastin) Ovarian Cancer – Patient Advocacy Group COI Declarations COI Declarations June 4, 2015 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : June 26, 2015